
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2018

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Massachusetts

(State or other jurisdiction
of incorporation)

001-38185

(Commission
File Number)

04-2652826

(IRS Employer
Identification No.)

14 Norfolk Avenue
South Easton, Massachusetts 02375
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (508) 230-1828

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On December 6, 2018, Pressure BioSciences, Inc. (the “Company”) held a special meeting in lieu of the annual meeting of stockholders (the “Meeting”). At the Meeting, the stockholders voted on the following proposals described in detail in the Company’s definitive proxy statement for the Meeting filed with the Securities and Exchange Commission on October 22, 2018. As of the record date for the Meeting, there were 1,648,904 shares of the Company’s common stock, par value \$0.01 per share, issued and outstanding and entitled to one vote for each share held. The holders of 65.78% of the Company’s shares of common stock outstanding (1,084,670) submitted votes by proxy or in person at the Meeting, constituting a quorum.

Proposal 1 — Elect two directors as a Class I Directors until the 2021 Annual Meeting of Stockholders. The election of the directors was approved as follows:

| <i>Nominee</i> | <i>For</i> | <i>Against</i> | <i>Shares voted</i> <i>Withhold</i> | <i>Broker Non-Votes</i> |
|---------------------|------------|----------------|--|-------------------------|
| Jeffrey N. Peterson | 390,557 | N/A | 21,811 | 672,302 |
| Michael S. Urdea | 394,443 | N/A | 17,925 | 672,302 |

Proposal 2: Ratify the appointment of MaloneBailey LLP as the Company’s independent auditors for fiscal year 2018. The ratification of the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2018 was approved as follows:

| | <i>Shares voted</i> |
|------------------|---------------------|
| For | 926,383 |
| Against | 4,462 |
| Abstain | 153,825 |
| Broker Non-Votes | N/A |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PRESSURE BIOSCIENCES, INC.

Dated: December 12, 2018

By: /s/ Richard T. Schumacher

Richard T. Schumacher
President
